Phase II trial of fludarabine in patients with epithelial ovarian cancer.
J J
JJ
Kavanagh
C A
CA
Stringer
L J
LJ
Copeland
D M
DM
Gershenson
P
P
Saul
D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D001088:Arabinonucleotides; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate